

TABLE OF CONTENTS

July 26, 2010

No. 2198

BUSINESS

- 1 Nippon Chemiphar Aims at Sales of ¥30.0 Bil. with Generics in FY2012
- Not Interested in Developing or Manufacturing Biosimilars
- 2 Drug Market in Japan to Grow 3-6% in 2010-2014: IMS Japan
- 3 Healthcare & Welfare Cooperative Union to Jointly Buy Drugs for Member Med Facilities
- 3 Market for Psychoneurotics to Expand to ¥453.2 Bil. in 2010: Fuji-Keizai
- 4 **BUSINESS NEWS IN BRIEF**
- US Diabetes Market Remains Attractive: Datamonitor
- Sepracor to Be Renamed Sunovion Pharmaceuticals
- Only 93 Apply for 750-Employee Early Retirement Program: Medipal
- 4 **NEW PRODUCTS**
- Lampion Pack Approved for Secondary Eradication of *H. Pylori*

GENERICS

- 5 Pariet to See Generics from 23 Companies in Nov.
- 5 Foreign-Affiliated Research-Driven Companies Point out Need for Cautious Approach to Generics Business

REGULATORY

- 6 Celgene's 2 Drugs for Multiple Myeloma Recommended for Approval
- 7 All Candidates from *Nichiiren* Fail to Obtain Seat in Upper House
- Votes for Candidates from *Nichiiren* Continue to Decrease
- Other Healthcare Providers' Organizations Secure Seats
- 7 Parliamentary Secretary for Health Shinya Adachi Reelected
- 8 Dr Fujii Regains Seat in Upper House
- To Make Recommendations as a Drug Professional
- JPA Has Great Hope for Dr Fujii: VP Yamamoto
- 8 Standardize Interpretation of 1980 Notification: *Chuikyo*
- 9 Industry Criticized Again at *Chuikyo* Meeting
- Questions Raised on Use of Drugs above Approved Upper Dosage Limits
- 10 Most Member Pharmacies Have Correctly Understood Significance of Premium: NPhA

- 10 Interest Shown in Development of 3 More Unapproved Drugs
- Procedures Explained to Interested Parties
- 11 OIG Asks FDA to Inspect More Overseas Trial Sites
- 12 Takeda Confident about Actos Data
- 13 **Commentary**
- Industry Needs to Form Consensus on Premium with Med. Institutions

MEDICAL DEVICES

- 12 Terumo Aims at Sales of ¥1 Tril. within 10 Years: New President Shintaku

R&D

- 14 Pfizer Signs Clinical Trial Partnership Agreement with NHO
- 14 **R&D NEWS IN BRIEF**
- Lorcaserin Induces Significant Weight Loss in PIII: Eisai
- JELIS Trial Sub-Analysis Shows Significant Reduction in CAD by Epedel
- Dapagliflozin + Insulin Improve Glycemic Control in PIII: BMS, AZ
- Everolimus More Than Doubles PFS in pNET Patients
- Iressa Doubles PFS in Japanese NSCLC Patients with Mutated EGFR
- 16 **Commentary**
- Japan Should Promote Personalized Cancer Treatment

SELF-MEDICATION

- 17 Kobayashi to Develop More Class 1 OTC Drugs
- 17 JPA to Renew Its Efforts to Increase Members' Awareness of New OTC Drug Sales System

MEDICAL FACILITIES & NURSING CARE

- 18 Erbitux Associated with Fewer Severe Infusion Reactions in Japan
- GL Recommends Erbitux as First-Line Treatment for CRC
- 18 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
- Test for Predicting Efficacy of IFN Recommended for Approval as Advanced Technology
- 19 **Survey**
- Use of New Drugs Increasing in Cancer Therapy: CareNet
- Use of Avastin Increasing for Colon Cancer
- Use of Sutent, Nexavar Increasing for RCC